COMP <GO>
IXHL vs ACET // EV/EBITDA & P/E VALUATION
Incannex Healthcare Inc. (NASDAQ) VS. Adicet Bio Inc. (NASDAQ) • 15-METRIC TALLY: IXHL 1
— ACET 2
■ METRIC PARITY
LAST: $2.58 (-4.80%) • MKT CAP: $32.4M
valuation
—
LAST: $3.58 (-6.04%) • MKT CAP: $33.5M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IXHL VS. ACET)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | IXHL | ACET | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 3/9 | -1.00 | ACET | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 29.0 | 18.5 | +10.51 | IXHL | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $32.4M | $33.5M | -$1.1M | ACET | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | IXHL REV | ACET REV | IXHL GROSS % | ACET GROSS % | IXHL FCF | ACET FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $0 | — | — | -$12.5M | -$97.0M |
| FY 2024 | $12.0K | $0 | — | — | -$16.1M | -$93.5M |
| FY 2023 | $0 | $0 | — | — | -$10.7M | -$93.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IXHL // BETA —
ACET // BETA —